Case series of glans injuries during voluntary medical male circumcision for HIV prevention - eastern and southern Africa, 2015-2018.


Journal

BMC urology
ISSN: 1471-2490
Titre abrégé: BMC Urol
Pays: England
ID NLM: 100968571

Informations de publication

Date de publication:
25 Apr 2020
Historique:
received: 06 11 2019
accepted: 08 04 2020
entrez: 27 4 2020
pubmed: 27 4 2020
medline: 5 3 2021
Statut: epublish

Résumé

Male circumcision confers partial protection against heterosexual HIV acquisition among men. The President's Emergency Plan for AIDS Relief (PEPFAR) has supported > 18,900,000 voluntary medical male circumcisions (VMMC). Glans injuries (GIs) are rare but devastating adverse events (AEs) that can occur during circumcision. To address this issue, PEPFAR has supported multiple interventions in the areas of surveillance, policy, education, training, supply chain, and AE management. Since 2015, PEPFAR has conducted surveillance of GIs including rapid investigation by the in-country PEPFAR team. This information is collected on standardized forms, which were reviewed for this analysis. Thirty-six GIs were reported from 2015 to 2018; all patients were < 15 years old (~ 0·7 per 100,000 VMMCs in this age group) with a decreasing annual rate (2015: 0.7 per 100,000 VMMCs; 2018: 0.4 per 100,000 VMMC; p = 0.02). Most (64%) GIs were partial or complete amputations. All amputations among 10-14 year-olds occurred using the forceps-guided (FG) method, as opposed to the dorsal-slit (DS) method, and three GIs among infants occurred using a Mogen clamp. Of 19 attempted amputation repairs, reattached tissue was viable in four (21%) in the short term. In some cases, inadequate DS method training and being overworked, were found. Following numerous interventions by PEPFAR and other stakeholders, GIs are decreasing; however, they have not been eliminated and remain a challenge for the VMMC program. Preventing further cases of complete and partial amputation will likely require additional interventions that prevent use of the FG method in young patients and the Mogen clamp in infants. Improving management of GIs is critical to optimizing outcomes.

Sections du résumé

BACKGROUND BACKGROUND
Male circumcision confers partial protection against heterosexual HIV acquisition among men. The President's Emergency Plan for AIDS Relief (PEPFAR) has supported > 18,900,000 voluntary medical male circumcisions (VMMC). Glans injuries (GIs) are rare but devastating adverse events (AEs) that can occur during circumcision. To address this issue, PEPFAR has supported multiple interventions in the areas of surveillance, policy, education, training, supply chain, and AE management.
METHODS METHODS
Since 2015, PEPFAR has conducted surveillance of GIs including rapid investigation by the in-country PEPFAR team. This information is collected on standardized forms, which were reviewed for this analysis.
RESULTS RESULTS
Thirty-six GIs were reported from 2015 to 2018; all patients were < 15 years old (~ 0·7 per 100,000 VMMCs in this age group) with a decreasing annual rate (2015: 0.7 per 100,000 VMMCs; 2018: 0.4 per 100,000 VMMC; p = 0.02). Most (64%) GIs were partial or complete amputations. All amputations among 10-14 year-olds occurred using the forceps-guided (FG) method, as opposed to the dorsal-slit (DS) method, and three GIs among infants occurred using a Mogen clamp. Of 19 attempted amputation repairs, reattached tissue was viable in four (21%) in the short term. In some cases, inadequate DS method training and being overworked, were found.
CONCLUSION CONCLUSIONS
Following numerous interventions by PEPFAR and other stakeholders, GIs are decreasing; however, they have not been eliminated and remain a challenge for the VMMC program. Preventing further cases of complete and partial amputation will likely require additional interventions that prevent use of the FG method in young patients and the Mogen clamp in infants. Improving management of GIs is critical to optimizing outcomes.

Identifiants

pubmed: 32334596
doi: 10.1186/s12894-020-00613-6
pii: 10.1186/s12894-020-00613-6
pmc: PMC7183662
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

45

Références

BJU Int. 2005 Nov;96(7):1109-13
pubmed: 16225538
J Pediatr Urol. 2013 Dec;9(6 Pt A):763-8
pubmed: 23137994
BMC Health Serv Res. 2015 Jun 18;15:235
pubmed: 26084777
Korean J Urol. 2011 Feb;52(2):147-9
pubmed: 21379434
MMWR Morb Mortal Wkly Rep. 2018 Mar 23;67(11):337-339
pubmed: 29565839
MMWR Morb Mortal Wkly Rep. 2016 Jan 22;65(2):36-7
pubmed: 26797167
BMC Urol. 2019 Jul 11;19(1):65
pubmed: 31296191
J Urol. 1997 Nov;158(5):1946-7
pubmed: 9334645
Urol Ann. 2014 Jan;6(1):85-7
pubmed: 24669132
Cochrane Database Syst Rev. 2009 Apr 15;(2):CD003362
pubmed: 19370585
Pediatrics. 2012 Sep;130(3):e756-85
pubmed: 22926175
Lancet. 2007 Feb 24;369(9562):643-56
pubmed: 17321310
Urology. 2011 Jun;77(6):1472-3
pubmed: 21256558

Auteurs

Todd J Lucas (TJ)

Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, GA, USA. tlucas@cdc.gov.
Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, GA, USA. tlucas@cdc.gov.
Division of Global HIV and Tuberculosis, Centers for Disease Control and Prevention, Atlanta, GA, USA. tlucas@cdc.gov.

Carlos Toledo (C)

Division of Global HIV and Tuberculosis, Centers for Disease Control and Prevention, Atlanta, GA, USA.

Stephanie M Davis (SM)

Division of Global HIV and Tuberculosis, Centers for Disease Control and Prevention, Atlanta, GA, USA.

D Heather Watts (DH)

U.S. Office of the Global HIV/AIDS Coordinator, Washington, D.C, USA.

Joseph S Cavanaugh (JS)

U.S. Office of the Global HIV/AIDS Coordinator, Washington, D.C, USA.

Valerian Kiggundu (V)

Office of HIV/AIDS, U.S. Agency for International Development, Washington, D.C, USA.

Anne G Thomas (AG)

Defense Health Agency, Department of Defense, San Diego, CA, USA.

Elijah Odoyo-June (E)

Division of Global HIV and Tuberculosis, Centers for Disease Control and Prevention, Nairobi, Kenya.

Collen Bonnecwe (C)

National Department of Health, Pretoria, South Africa.

Tintswalo Hilda Maringa (TH)

Division of Global HIV and Tuberculosis, Centers for Disease Control and Prevention, Pretoria, South Africa.

Enilda Martin (E)

U.S. Agency for International Development, Pretoria, South Africa.

Ambrose Wanyonyi Juma (AW)

National AIDS and STI Control Program, Ministry of Health, Nairobi, Kenya.

Sinokuthemba Xaba (S)

Ministry of Health and Child Care, Harare, Zimbabwe.

Shirish Balachandra (S)

Division of Global HIV and Tuberculosis, Centers for Disease Control and Prevention, Harare, Zimbabwe.

Jotamo Come (J)

Ministry of Health, Maputo, Mozambique.

Marcos Canda (M)

Division of Global HIV and Tuberculosis, Centers for Disease Control and Prevention, Maputo, Mozambique.

Rose Nyirenda (R)

Ministry of Health, Lilongwe, Malawi.

Wezi Msungama (W)

Division of Global HIV and Tuberculosis, Centers for Disease Control and Prevention, Lilongwe, Malawi.

James Odek (J)

U.S. Agency for International Development, Lilongwe, Malawi.

Gissenge J I Lija (GJI)

National AIDS Control Program, Ministry of Health, Community Development, Gender, Elderly and Children, Dar es Salaam, Tanzania.

Erick Mlanga (E)

U.S. Agency for International Development, Dar es Salaam, Tanzania.

James Exnobert Zulu (JE)

Ministry of Health, Lusaka, Zambia.

Heidi O'Bra (H)

U.S. Agency for International Development, Lusaka, Zambia.

Omega Chituwo (O)

Division of Global HIV and Tuberculosis, Centers for Disease Control and Prevention, Lusaka, Zambia.

Mekondjo Aupokolo (M)

Ministry of Health and Social Services, Windhoek, Namibia.

Denis A Mali (DA)

U.S. Agency for International Development, Windhoek, Namibia.

Brigitte Zemburuka (B)

Division of Global HIV and Tuberculosis, Centers for Disease Control and Prevention, Windhoek, Namibia.

Kananga Dany Malaba (KD)

Division of Global HIV and Tuberculosis, Centers for Disease Control and Prevention, Gaborone, Botswana.

Onkemetse Conrad Ntsuape (OC)

Ministry of Health and Wellness, Gaborone, Botswana.

Jonas Z Hines (JZ)

Division of Global HIV and Tuberculosis, Centers for Disease Control and Prevention, Atlanta, GA, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH